Mobile

Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-mo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001960-30

Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-month randomised double-blind parallel-group international multicentre study

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that after a 4-month treatment period ivabradine (5 mg b.i.d. given orally for 2 months then 7.5 mg b.i.d. given orally for other 2 months) is more efficacious than placebo when given in combination with atenolol alone (50 mg o.d.) in patients with stable chronic effort angina pectoris previously treated by atenolol 50 mg o.d. (or another beta-blocker at a dosage equivalent to 50 mg of atenolol o.d.).

Critère d'inclusion

  • stable angina pectoris

Liens